|
|
|
|
original piano music
Runtime: 6m23s
Views: 1077 |
Comments: 1
|
|
|
|
|
Original music piano and trumpet
Runtime: 3m14s
Views: 1787 |
Comments: 1
|
|
|
|
|
Original music w drum
Runtime: 4m28s
Views: 1911 |
Comments: 1
|
|
|
|
|
original music on piano
Runtime: 4m52s
Views: 1832 |
Comments: 1
|
|
|
|
|
WebMD Health Corp. (NASDAQ:WBMD), the leading source of health information, today announced the premiere of WebMD’s Future of Health with Robin Roberts, developed in collaboration with Good Morning America co-anchor Robin Roberts and her independent production company, Rock’n Robin Productions. Each Future of Health episode presents stories about cutting-edge medical breakthroughs, inspiring individuals working to improve people’s lives, and the people that are benefiting from their efforts. The five-part digital video series and related programming, which include feature stories, slideshows, quizzes and a host of video extras, are available at http://webmd.com/futureofhealth.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7282551-webmd-future-of-health/
Runtime: 1m51s
Views: 1494 |
Comments: 1
|
|
|
|
|
Original music on guitars
Runtime: 2m20s
Views: 862 |
Comments: 1
|
|
|
|
|
original guitar music
Runtime: 4m8s
Views: 1025 |
Comments: 1
|
|
|
|
|
original blues guitars
Runtime: 4m11s
Views: 1159 |
Comments: 1
|
|
|
|
|
Original music on piano
Runtime: 5m48s
Views: 1611 |
Comments: 1
|
|
|
|
|
Original music on piano
Runtime: 4m56s
Views: 1717 |
Comments: 1
|
|
|
|
|
original piano music
Runtime: 9m54s
Views: 1767 |
Comments: 1
|
|
|
|
|
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Runtime: 4m34s
Views: 1376 |
Comments: 0
|
